A5108053413- Platelet Disorders and Treatments
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Blood groups and transfusion
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Mesenchymal stem cell research
- Blood properties and coagulation
- Complement system in diseases
- Cytomegalovirus and herpesvirus research
- Bone and Joint Diseases
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Multiple Myeloma Research and Treatments
- Animal Behavior and Welfare Studies
- Renal Diseases and Glomerulopathies
- Autoimmune Bullous Skin Diseases
- Childhood Cancer Survivors' Quality of Life
- Lipid metabolism and disorders
- Hepatitis C virus research
- Extracellular vesicles in disease
- Hematological disorders and diagnostics
- Gut microbiota and health
Peking University
2016-2025
Peking University People's Hospital
2016-2025
Second Affiliated Hospital of Zhejiang University
2021-2025
Zhejiang University
2012-2025
Shaanxi Normal University
2025
National Clinical Research Center for Digestive Diseases
2019-2024
Moffitt Cancer Center
2012-2024
National Clinical Research
2024
First Hospital of Xi'an
2023
Xian Central Hospital
2023
Ex vivo-expanded mesenchymal stem cells (MSCs) have been demonstrated to be a heterogeneous mixture of exhibiting varying proliferative, multipotential, and immunomodulatory capacities. However, the exact characteristics MSCs remain largely unknown. By single-cell RNA sequencing 61,296 derived from bone marrow Wharton's jelly, we revealed five distinct subpopulations. The developmental trajectory these MSC subpopulations was mapped, revealing differentiation path stem-like active...
Steroid-resistant (SR) acute graft-versus-host disease (aGVHD) lacks standard second-line treatment. Mesenchymal stromal cells (MSCs) have potential efficacy in SR aGVHD. We aimed to assess the and safety of MSCs combined with basiliximab calcineurin inhibitor as therapy for
BACKGROUND Antithymocyte globulin (ATG) is an important component of conditioning regimens to prevent severe graft‐versus‐host disease (GVHD) in patients undergoing unmanipulated, haploidentical stem cell transplantation (haplo‐SCT). However, the authors' knowledge, optimal dose ATG unknown. METHODS In this prospective, randomized trial, authors compared long‐term outcomes 2 doses (rabbit thymoglobulin) used myeloablative before unmanipulated haplo‐HSCT. Patients were randomly assigned (1:1)...
Previous studies have suggested that mesenchymal stromal cells (MSCs) enhance the engraftment of hematopoietic stem and modulate host's immune response. However, there are no randomized to confirm these results. Moreover, some concerns about risk tumor recurrence because immunosuppressive property MSCs. We conducted an open-label, phase II clinical study assess outcome MSC coinfusion (3-5 × 10(5) cells/kg) during haploidentical cell transplantation. From June 2007 2008, a total 55 patients...
Metastasis contributes to the poor prognosis of colorectal cancer, causative factor which is not fully understood. Previously, we found that miR-125b (Accession number: MIMAT0000423) contributed cetuximab resistance in cancer (CRC). In this study, identified a novel mechanism by enhances metastasis targeting cystic fibrosis transmembrane conductance regulator (CFTR) and tight junction-associated adaptor cingulin (CGN) CRC. We expression was upregulated primary CRC tumors metastatic sites...
Doxorubicin (DOX) has received attention due to dose-dependent cardiotoxicity through abnormal redox cycling. Native fibroblast growth factor 1 (FGF1) is known for its anti-oxidative benefits in cardiovascular diseases, but possesses a potential tumorigenic risk. Coincidentally, the anti-proliferative properties of resveratrol (RES) have attracted as alternatives or auxiliary therapy when combined with other chemotherapeutic drugs. Therefore, purpose this study explore therapeutic and...
Abstract Experience using olverembatinib as maintenance therapy in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph + ALL) after allogeneic hematopoietic cell transplantation (allo-HCT) is limited. We retrospectively collected data from 26 Ph ALL who received only allo-HCT. Olverembatinib was administered prophylaxis 18 (69.2%), and preemptively 8 (30.8%). The median time of initiation 2.5 months (range, 1-7.3). starting dose 35 mg qod 15–40). duration...
The outcomes are poor for paediatric patients with T-cell acute lymphoblastic leukaemia (T-ALL) who relapse after haematopoietic stem cell transplantation (HSCT). However, studies focusing on T-ALL following haploidentical HSCT (haplo-HSCT) limited. We retrospectively identified a consecutive cohort comprising of 128 haplo-HSCT from 2642 ALL between January 2010 and June 2022. 2-year overall survival leukaemia-free were 67.77% ± 4.21% 66.34% 3.82%, respectively, the cumulative incidence...
Corticosteroids (CSs) are the initial therapy for immune thrombocytopenia (ITP); however, their efficacy is not adequately predicted. As a novel biomarker, composition of gut microbiota non-invasively tested and altered in patients with ITP. This study aims to develop predictive model that leverages microbiome data predict CS response ITP within four weeks treatment. Metagenomic sequencing performed on fecal samples from 212 ITP, 152 whom underwent treatment follow-up. Predictive models...
PURPOSE The aim of this open-label, multicenter, randomized controlled trial was to determine the efficacy and safety sequential umbilical cord–derived mesenchymal stem cell (UC-MSC) infusion for graft-versus-host disease (GVHD) prevention within 3 months haploidentical hematopoietic transplantation (haplo-HSCT). METHODS This open-label study evaluated UC-MSC (administer 1 × 10 6 /kg 4 hours before commencement day 0, once weekly first month after transplantation, every 2 weeks second month,...
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a well-established curative treatment option for acute myeloid leukemia (AML) in second complete remission (CR2). However, whether the addition of consolidation chemotherapy after achieving CR2 can improve transplant outcomes remains controversial. Methods: In this single-center retrospective study, we analyzed consecutive AML patients who underwent their first HSCT at our institution between January 2015 and December...
Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by a reduced platelet count and increased risk of bleeding. Although immense research has improved our understanding ITP, the pathogenesis remains unclear. Here, we investigated involvement 25 single-nucleotide polymorphisms (SNPs) inflammation-related genes, including CD24, CD226, FCRL3, IL2, IRF5, ITGAM, NLRP3, CARD8, PTPN22, SH2B2, STAT4, TNFAIP3, TRAF1, in treatment response ITP. We recruited 312 ITP...
Rare but critical bleeding events in primary immune thrombocytopenia (ITP) present life-threatening complications patients with ITP, which severely affect their prognosis, quality of life, and treatment decisions. Although several studies have investigated the risk factors related to large sample size data, consistent definitions, large-scale multicenter findings, prediction models for ITP are unavailable. For first time, this study, we applied newly proposed criteria by International...
Abstract Recent findings have shown that the level of interleukin‐35 (IL‐35) is abnormal in several autoimmune diseases. Nonetheless, whether IL‐35 participates pathogenesis immune thrombocytopenia (ITP) remains unclear. The current study investigates modulates megakaryopoiesis. results show receptors are progressively expressed on bone marrow megakaryocytes during vitro differentiation CD34+ progenitors. increases number megakaryocyte colony‐forming units through Akt pathway. reduced ITP...